The ALS Ice Bucket Challenge, the viral social media ALS fundraising campaign, has transformed the ALS funding landscape. How exactly the funds will be used to advance ALS research is still in the works, but Steve Perrin, President and CEO of the non-profit biotechnology company, the ALS Therapy Institute (ALSTDI), has announced that half of the three million dollars the company has raised will go toward funding a new clinical trial in ALS. The identity of the drug has not yet been revealed, but it will be the second drug ever to be brought into human clinical trials by the biotech company after the repurposed multiple sclerosis drug Gilenya. Another one million dollars will go to fund ALSTDI’s newly launched precision medicine program.
Click here to read more.Share this: